Literature DB >> 26422286

Iron Overload in Survivors of Childhood Cancer.

Ashley Schempp1, Jill Lee, Susan Kearney, Daniel A Mulrooney, Angela R Smith.   

Abstract

Iron overload is a significant cause of morbidity and mortality for patients who require frequent transfusions. We completed a prospective, cross-sectional study to evaluate the prevalence of iron overload in previously transfused childhood cancer survivors. Survivors recruited from the University of Minnesota Long-Term Follow-Up Clinic were stratified into 3 groups: oncology patients not treated with hematopoietic stem cell transplantation (HSCT) (n=27), patients treated with allogeneic HSCT (n=27), and patients treated with autologous HSCT (n=9). Serum ferritin was collected and hepatic magnetic resonance imaging (FerriScan) was obtained for those with iron overload (defined as ferritin ≥1000 ng/mL). The prevalence of iron overload in subjects with a history of allogeneic HSCT was 25.9% (95% CI, 9.4%-42.5%) compared with only 3.7% (95% CI, 0%-10.8%) in subjects treated without HSCT and 0% in subjects treated with autologous HSCT. No association was found between serum ferritin levels and the presence of cardiac, liver, or endocrine dysfunction. The prevalence of iron overload in subjects who received no HSCT or autologous HSCT is low in our study. A higher prevalence was found in patients receiving allogeneic HSCT, reiterating the importance of screening these patients for iron overload in accordance with the current Children's Oncology Group Long Term Follow-Up Guidelines.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26422286     DOI: 10.1097/MPH.0000000000000444

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  5 in total

1.  Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors:  Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-15

2.  Cardiac dysfunction in medulloblastoma survivors treated with photon irradiation.

Authors:  Chantel Cacciotti; Christine Chordas; Katie Valentino; Rudy Allen; Alicia Lenzen; Karen Burns; Rajaram Nagarajan; Peter Manley; Natasha Pillay-Smiley
Journal:  Neurooncol Pract       Date:  2022-04-23

3.  Blood product administration during high risk neuroblastoma therapy.

Authors:  Allison Silverstein; Kiranmye Reddy; Valeria Smith; Jennifer H Foster; Heidi V Russell; Sarah B Whittle
Journal:  Pediatr Hematol Oncol       Date:  2019-12-12       Impact factor: 1.969

4.  Evaluation of Liver Iron Content by Magnetic Resonance Imaging in Children with Acute Lymphoblastic Leukemia after Cessation of Treatment

Authors:  Sezer Acar; Salih Gözmen; Selen Bayraktaroğlu; Sultan O. Acar; Neryal Tahta; Yeşim Aydınok; Raziye C. Vergin
Journal:  Turk J Haematol       Date:  2020-02-20       Impact factor: 1.831

5.  Assessment of Obesity and Hepatic Late Adverse Effects in the Egyptian Survivors of Pediatric Acute Lymphoblastic Leukemia: a Single Center Study.

Authors:  Farida H El-Rashedy; Mahmoud A El-Hawy; Sally M El Hefnawy; Mona M Mohammed
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-04-15       Impact factor: 2.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.